Zacks.com on MSN21h
Merck Gets Positive CHMP Opinion for Keytruda in MesotheliomaCommittee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion, recommending the approval of its ...
GlobalData on MSN4d
EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myelomaCommittee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade ...
Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.
Statement/Regulatory AdmissionFormycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama® 18.11.2024 / 06:30 ...
BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...
The CHMP has recommended the Rybrevant-Lazcluze combination as ... which is the current standard of care for EGFR-mutated ...
4d
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...
Zacks.com on MSN3d
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in EuropeBiogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...
1 Eisai had requested a re-examination of the prior negative opinion adopted by the CHMP in July 2024. In accordance with European Medicines Agency regulatory process, the European Commission is ...
Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of ...
1 Eisai had requested a re-examination of the prior negative opinion adopted by the CHMP in July 2024. In accordance with European Medicines Agency regulatory process, the European Commission is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback